X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (72106) 72106
Book Review (12048) 12048
Publication (3794) 3794
Newsletter (1040) 1040
Newspaper Article (518) 518
Magazine Article (341) 341
Book Chapter (266) 266
Conference Proceeding (122) 122
Book / eBook (74) 74
Dissertation (45) 45
Trade Publication Article (37) 37
Reference (30) 30
Web Resource (11) 11
Transcript (8) 8
Paper (5) 5
Data Set (4) 4
Government Document (2) 2
Presentation (2) 2
Journal / eJournal (1) 1
Video Recording (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (64494) 64494
humans (46571) 46571
male (33992) 33992
animals (27711) 27711
female (26531) 26531
anti-inflammatory agents - therapeutic use (16283) 16283
adult (15265) 15265
anti-inflammatory agents - administration & dosage (14803) 14803
middle aged (14022) 14022
pharmacology & pharmacy (13751) 13751
anti-inflammatory agents, non-steroidal - administration & dosage (12280) 12280
rats (12058) 12058
anti-inflammatory agents, non-steroidal - therapeutic use (11550) 11550
anti-inflammatory agents - pharmacology (11054) 11054
inflammation (10644) 10644
mice (10616) 10616
aged (9573) 9573
treatment outcome (8764) 8764
anti-inflammatory agents, non-steroidal - pharmacology (7113) 7113
anti-inflammatory agents, non-steroidal - adverse effects (7018) 7018
administration, topical (6637) 6637
abridged index medicus (6615) 6615
dose-response relationship, drug (5835) 5835
analysis (5604) 5604
nonsteroidal anti-inflammatory drugs (5536) 5536
disease models, animal (5522) 5522
adolescent (5408) 5408
anti-inflammatory drugs (5335) 5335
time factors (5059) 5059
administration, oral (4759) 4759
double-blind method (4677) 4677
care and treatment (4609) 4609
immunology (4574) 4574
research (4374) 4374
anti-inflammatory agents - adverse effects (4272) 4272
rats, wistar (4251) 4251
drug therapy, combination (4207) 4207
nonsteroidal antiinflammatory drugs (4195) 4195
child (3884) 3884
drug therapy (3858) 3858
pain (3815) 3815
chemistry, medicinal (3799) 3799
rats, sprague-dawley (3694) 3694
risk factors (3616) 3616
health aspects (3582) 3582
inflammation - drug therapy (3523) 3523
expression (3505) 3505
medicine, general & internal (3249) 3249
cytokines (3210) 3210
surgery (3199) 3199
corticosteroids (3153) 3153
glucocorticoids (3132) 3132
therapy (3106) 3106
gastroenterology & hepatology (3076) 3076
anti-inflammatory (3051) 3051
medicine & public health (3010) 3010
double-blind (2988) 2988
drugs (2980) 2980
dosage and administration (2968) 2968
prospective studies (2936) 2936
oxidative stress (2920) 2920
inhibition (2818) 2818
rheumatology (2774) 2774
biochemistry & molecular biology (2737) 2737
drug administration schedule (2733) 2733
anti-inflammatory agents, non-steroidal - pharmacokinetics (2689) 2689
rheumatoid-arthritis (2620) 2620
disease (2598) 2598
aged, 80 and over (2551) 2551
neurosciences (2548) 2548
in-vitro (2478) 2478
dermatology (2464) 2464
steroids (2462) 2462
cells (2449) 2449
follow-up studies (2443) 2443
arthritis (2385) 2385
nf-kappa-b (2363) 2363
aspirin (2355) 2355
young adult (2331) 2331
rodents (2327) 2327
plant extracts - pharmacology (2313) 2313
activation (2293) 2293
retrospective studies (2260) 2260
analgesics (2256) 2256
anti-inflammatory agents, non-steroidal - chemistry (2215) 2215
efficacy (2190) 2190
mice, inbred c57bl (2151) 2151
prevention (2129) 2129
cell biology (2122) 2122
asthma - drug therapy (2115) 2115
child, preschool (2105) 2105
asthma (2097) 2097
apoptosis (2074) 2074
pain measurement (2054) 2054
edema - drug therapy (2029) 2029
pharmacology/toxicology (2023) 2023
antioxidants (2020) 2020
cancer (2011) 2011
anti-inflammatory agents - chemistry (2002) 2002
internal medicine (2001) 2001
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (52) 52
Sunnybrook Health Sciences Centre - Holland Stacks (2) 2
UTL at Downsview - May be requested (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Media Commons - Audio Visual (1) 1
Mt Sinai Hospital - Online (1) 1
Online Resources - Online (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (67609) 67609
German (1756) 1756
Japanese (992) 992
French (988) 988
Russian (819) 819
Spanish (418) 418
Italian (377) 377
Chinese (273) 273
Polish (249) 249
Danish (125) 125
Swedish (103) 103
Hungarian (87) 87
Dutch (76) 76
Norwegian (67) 67
Portuguese (65) 65
Turkish (54) 54
Czech (49) 49
Romanian (40) 40
Ukrainian (33) 33
Bulgarian (30) 30
Finnish (27) 27
Croatian (24) 24
Korean (23) 23
Hebrew (19) 19
Lithuanian (16) 16
Serbian (16) 16
Slovak (6) 6
Arabic (3) 3
Afrikaans (2) 2
Bosnian (1) 1
Greek (1) 1
Icelandic (1) 1
Indonesian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Controlled Release, ISSN 0168-3659, 06/2015, Volume 207, pp. 18 - 30
Exosomes are naturally occurring nanosized vesicles that have attracted considerable attention as drug delivery vehicles in the past few years. Exosomes are... 
Oxidative stress | Neuroinflammation | Parkinson's disease | Catalase | Exosomes | Blood–brain barrier | Blood-brain barrier | ALZHEIMERS-DISEASE | REPEATED INJECTIONS | MACROPHAGE DELIVERY | MEDIATED TRANSFER | BLOOD-BRAIN-BARRIER | BIOLOGICAL BARRIERS | CHEMISTRY, MULTIDISCIPLINARY | IN-VITRO | PEGYLATED LIPOSOMES | PHARMACOLOGY & PHARMACY | SUPEROXIDE-DISMUTASE | Antioxidants - chemistry | Antioxidants - metabolism | Oxidopamine | Anti-Inflammatory Agents - metabolism | PC12 Cells | Neuroprotective Agents - metabolism | Drug Carriers | Brain - metabolism | Nanoparticles | Parkinsonian Disorders - metabolism | Parkinsonian Disorders - drug therapy | Antiparkinson Agents - chemistry | Anti-Inflammatory Agents - administration & dosage | Female | Neurons - metabolism | Neuroprotective Agents - administration & dosage | Nanomedicine | Disease Models, Animal | Neuroprotective Agents - chemistry | Mice, Inbred C57BL | Solubility | Rats | Technology, Pharmaceutical - methods | Parkinsonian Disorders - chemically induced | Administration, Intranasal | Chemistry, Pharmaceutical | Brain - drug effects | Catalase - metabolism | Catalase - administration & dosage | Animals | Anti-Inflammatory Agents - chemistry | Antioxidants - administration & dosage | RAW 264.7 Cells | Antiparkinson Agents - administration & dosage | Mice | Kinetics | Oxidative Stress - drug effects | Antiparkinson Agents - metabolism | Catalase - chemistry | Drugs | Drug delivery systems | Proteases | Analysis | Antiparkinsonian agents | Vehicles | Index Medicus
Journal Article
Gastroenterology, ISSN 0016-5085, 2015, Volume 148, Issue 7, pp. 1320 - 1329.e3
Background & Aims Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn’s disease (CD) and ulcerative colitis (UC). We... 
Gastroenterology and Hepatology | Personalized Medicine | Pharmacokinetics | Therapeutic Drug Monitoring | Monoclonal Antibody | DOSE INTENSIFICATION | MAINTENANCE | THERAPY | CROHNS-DISEASE | EFFICACY | GASTROENTEROLOGY & HEPATOLOGY | ASSOCIATION | WITHDRAWAL | Drug Costs | Recurrence | Crohn Disease - economics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gastrointestinal Agents - administration & dosage | Male | Colitis, Ulcerative - immunology | Gastrointestinal Agents - economics | Antibodies, Monoclonal - blood | Drug Dosage Calculations | Anti-Inflammatory Agents - adverse effects | Infliximab | Crohn Disease - diagnosis | Adult | Anti-Inflammatory Agents - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Female | Colitis, Ulcerative - drug therapy | Gastrointestinal Agents - pharmacokinetics | Anti-Inflammatory Agents - economics | Tertiary Care Centers | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Colitis, Ulcerative - blood | Crohn Disease - immunology | Remission Induction | Anti-Inflammatory Agents - blood | Algorithms | Belgium | Colitis, Ulcerative - diagnosis | Antibodies, Monoclonal - administration & dosage | Cost-Benefit Analysis | Crohn Disease - blood | Crohn Disease - drug therapy | Gastrointestinal Agents - adverse effects | Gastrointestinal Agents - blood | Colitis, Ulcerative - economics | Drug Monitoring | Antibodies, Monoclonal - economics | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Care and treatment | Continuing medical education | Consulting services | Ulcerative colitis | Index Medicus | Abridged Index Medicus
Journal Article
Gastroenterology, ISSN 0016-5085, 2008, Volume 134, Issue 7, pp. 1861 - 1868
Background & Aims: The benefit to risk ratio of concomitant immunosuppressives with scheduled infliximab (IFX) maintenance therapy for Crohn's disease is an... 
Gastroenterology and Hepatology | RHEUMATOID-ARTHRITIS | ANTIBODIES | MULTICENTER | INFLAMMATORY-BOWEL-DISEASE | THERAPY | SERUM INFLIXIMAB | LYMPHOMA | RISK | INDUCTION | GASTROENTEROLOGY & HEPATOLOGY | SHORT-TERM | Azathioprine - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gastrointestinal Agents - administration & dosage | Crohn Disease - metabolism | Male | Intestinal Mucosa - drug effects | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Infliximab | Adult | Anti-Inflammatory Agents - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Female | Drug Therapy, Combination | France | Gastrointestinal Agents - pharmacokinetics | Immunosuppressive Agents - administration & dosage | Drug Administration Schedule | Mercaptopurine - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Belgium | Antibodies, Monoclonal - administration & dosage | Crohn Disease - pathology | Crohn Disease - drug therapy | Methotrexate - administration & dosage | Gastrointestinal Agents - adverse effects | Infusions, Intravenous | Intestinal Mucosa - pathology | Clinical trials | Crohn's disease | C-reactive protein | Tumor necrosis factor | Immunotherapy | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Hépatology and Gastroenterology
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 6/2011, Volume 52, Issue 11, pp. 1374 - 1383
Background. The optimal time to initiate antiretroviral therapy (ART) in human immunodeficiency virus (HIV)—associated tuberculous meningitis is unknown.... 
Statistical median | HIV/AIDS | Antiretrovirals | Art therapy | Meningeal tuberculosis | HIV | Mortality | Random allocation | AIDS | Arts | HIV 1 | MORTALITY | SURVIVAL | THAILAND | INFECTIOUS DISEASES | HIV-INFECTION | ERA | ADOLESCENTS | CLINICAL-TRIALS | ADULTS | RISK | MICROBIOLOGY | IMMUNOLOGY | Lamivudine - administration & dosage | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Male | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | Time Factors | Adult | Anti-Inflammatory Agents - administration & dosage | Female | HIV Infections - mortality | Antiretroviral Therapy, Highly Active - methods | Tuberculosis, Meningeal - mortality | Placebos - administration & dosage | Dexamethasone - administration & dosage | Tuberculosis, Meningeal - drug therapy | Benzoxazines - administration & dosage | Double-Blind Method | Trimethoprim, Sulfamethoxazole Drug Combination - administration & dosage | Anti-HIV Agents - adverse effects | Treatment Outcome | Tuberculosis, Meningeal - complications | HIV Infections - complications | Antitubercular Agents - administration & dosage | HIV Infections - drug therapy | Antiviral agents | Care and treatment | Patient outcomes | Dosage and administration | Drug therapy | Health aspects | HIV infection | Comorbid patients | Tuberculous meningitis | Clinical trials | Antiretroviral drugs | Meningitis | Human immunodeficiency virus--HIV | Risk assessment | Medical treatment | Index Medicus
Journal Article
Gastroenterology, ISSN 0016-5085, 2012, Volume 142, Issue 1, pp. 63 - 70.e5
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 04/2014, Volume 73, Issue 4, pp. 710 - 715
Objective Compare the radiographic progression of ankylosing spondylitis (AS) patients treated with infliximab (INF) versus historical controls (Herne cohort,... 
RADIOGRAPHIC PROGRESSION | NECROSIS-FACTOR | ASAS RECOMMENDATIONS | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | INFLAMMATION | DOUBLE-BLIND | RESONANCE-IMAGING PREDICT | RHEUMATOLOGY | INFLIXIMAB | AXIAL SPONDYLOARTHRITIS | CLINICAL-RESPONSE | Single-Blind Method | Follow-Up Studies | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Infliximab | Adult | Female | Retrospective Studies | Antirheumatic Agents - pharmacology | Cervical Vertebrae - physiopathology | Lumbar Vertebrae - physiopathology | Antirheumatic Agents - therapeutic use | Cervical Vertebrae - diagnostic imaging | Drug Administration Schedule | Lumbar Vertebrae - diagnostic imaging | Antibodies, Monoclonal - pharmacology | Osteogenesis - drug effects | Spondylitis, Ankylosing - drug therapy | Treatment Outcome | Spondylitis, Ankylosing - physiopathology | Disease Progression | Spondylitis, Ankylosing - diagnostic imaging | Radiography | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Antibodies, Monoclonal - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Observer Variation | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Care and treatment | Usage | Dosage and administration | Tumor necrosis factor inhibitors | Ankylosing spondylitis | Tumor necrosis factor-TNF | Hypotheses | Inflammation | Patients | Colleges & universities | Index Medicus
Journal Article
Journal of Investigative Dermatology, ISSN 0022-202X, 05/2013, Volume 133, Issue 5, pp. 1231 - 1239
Advances in nanotechnology have demonstrated potential application of nanoparticles (NPs) for effective and targeted drug delivery. Here we investigated the... 
WATER-SOLUBLE CHITOSAN | ANTIBACTERIAL PROPERTIES | MICROSPHERES | ALPHA | ACNE-VULGARIS | RELEASE | MICROPARTICLES | NANOTECHNOLOGY | DELIVERY | DERMATOLOGY | Alginates - therapeutic use | Anti-Infective Agents - pharmacology | Humans | Hexuronic Acids - administration & dosage | Skin Diseases, Bacterial - drug therapy | Drug Delivery Systems | Feasibility Studies | Nanoparticles - therapeutic use | Chitosan - therapeutic use | Anti-Inflammatory Agents - therapeutic use | Chitosan - pharmacology | Anti-Inflammatory Agents - administration & dosage | Glucuronic Acid - administration & dosage | Keratinocytes - microbiology | Alginates - pharmacology | Benzoyl Peroxide - pharmacology | Cell Line | Benzoyl Peroxide - administration & dosage | Benzoyl Peroxide - therapeutic use | Cytokines - metabolism | Anti-Inflammatory Agents - pharmacology | Propionibacterium acnes - physiology | Cells, Cultured | Chitosan - administration & dosage | Acne Vulgaris - drug therapy | Anti-Infective Agents - therapeutic use | Glucuronic Acid - therapeutic use | Alginates - administration & dosage | Glucuronic Acid - pharmacology | Anti-Infective Agents - administration & dosage | Keratinocytes - drug effects | Propionibacterium acnes - ultrastructure | Keratinocytes - metabolism | Nanoparticles - administration & dosage | Propionibacterium acnes - drug effects | Administration, Topical | Hexuronic Acids - pharmacology | Hexuronic Acids - therapeutic use | Index Medicus | Acne | Antimicrobial | Inflammation | Chitosan | Nanoparticle | Skin infection
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9766, pp. 650 - 657
Journal Article
Blood, ISSN 0006-4971, 04/2009, Volume 113, Issue 15, pp. 3435 - 3442
Journal Article
JAMA, ISSN 0098-7484, 02/2016, Volume 315, Issue 5, pp. 469 - 479
Journal Article